Spatial biomarkers are making their mark on oncology drug development. By quantifying the spatial heterogeneity within tumor tissues, predictive spatial scores can help identify relationships between ...

Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the ...

The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...

The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...

A study by the Neuropsychopharmacology and IBeA groups of the University of the Basque Country (UPV/EHU) paves the way to ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

Skin surface biomarkers are increasingly recognised as essential measuring tools in dermatological science for non-invasive ...

The firm's LLM-based platform abstracted complex information from medical charts with up to 100 percent accuracy in a pilot study of breast cancer patients.

The Cell-Based Assays Market is projected to grow from $35.3 billion in 2024 to $56.3 billion by 2029, at a 9.8% CAGR, driven by demand for drug discovery, ADME/toxicity testing, and precision ...

Shares of Elevation Oncology , Inc. (NASDAQ: ELEV) fell by 20% following the announcement that the company will discontinue the development of its drug candidate EO-3021. The decision came after ...